What's it like to build the software in a brand-new sequencer? Illumina's Aneesh Natarajan takes us on the journeyOriginally published on Illumina News Center NORTHAMPTON, MA / ACCESS Newswire / ...

It’s been a busy week for Illumina at the JP Morgan 2025 Healthcare conference, with the company revealing partnerships and ...

Cancer is a disease of the genome, according to Dr. Elli Papaemmanuil, computational oncologist at MSK. By looking at the ...

At the J.P. Morgan Chase Health Care conference in San Francisco on Tuesday, Illumina CEO Jacob Thaysen touched on the ...

Illumina launches pilot proteomics programme with UK Biobank and biopharma collaborators to analyze 50,000 samples: San Diego Tuesday, January 14, 2025, 13:00 Hrs [IST] Illumina, ...

Illumina, Inc., a leader in DNA sequencing and array technologies, has launched a pilot proteomics program analyzing 50,000 ...

Illumina (ILMN) announced it is collaborating with Nvidia (NVDA) to advance technology platforms for the analysis and interpretation of ...

In a report released today, Tejas Savant from Morgan Stanley maintained a Hold rating on Illumina (ILMN – Research Report), with a price target ...

Macrogen has pioneered genome sequencing and testing in Korea, becoming a reference company and supporting the development of technology in the country. However, it would be wrong to limit Macrogen's ...

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a series of updates to its NovaSeq X Series, delivering the NovaSeq X single-flow-cell ...

A number of other research analysts have also commented on the company. Stephens raised their price target on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a ...